CompletedEUCTR 2015-003331-36
A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of self-administered ADASUVE(R) (Staccato loxapine for inhalation) in Agitated Patients outside the hospital setting
This historical record does not confirm current site availability.
Historical research recordAustria + NorwaySchizophrenia
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Austria · Norway
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 500
- Sponsor
- FERRER INTERNACIONAL SA
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Austria, Norway
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2015-003331-36
- Official title
Show the full official title
A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of self-administered ADASUVE(R) (Staccato loxapine for inhalation) in Agitated Patients outside the hospital setting
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedAustria · Norway
Questions about this study
Who is behind this study?
The study sponsor is FERRER INTERNACIONAL SA.
Want to explore more studies?
Explore studiesRelated studies
A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolarity type I
Elevated elimination rates of quetiapine in adolescent patients with schizophrenia (ICD 10: F 20.-), Bipolarity (ICD 10: F 31.-), disorders in impulse control with current PTSD (ICD...